PARIS, France—High residual platelet reactivity after a 600-mg loading dose of clopidogrel strongly predicts long-term cardiac mortality and thrombotic events in patients with acute coronary syndromes ...
Among patients scheduled for PCI who do not respond to clopidogrel, switching to prasugrel reduces the likelihood of having high residual platelet reactivity, according to the RECLOSE-3 study ...
September 20, 2011 (Florence, Italy) — The RECLOSE 2 ACS trial, confirming that high residual platelet reactivity on clopidogrel in ACS patients undergoing PCI is associated with increased event rates ...
Consumers demand it, brands want it and own brands are catching up fast. So why given the importance of reclose for flexible packaging is it often an afterthought or just a box to be ticked? So much ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results